
Quarterly report 2024-Q3
added 11-07-2024
Revance Therapeutics Market Cap 2011-2026 | RVNC
As of April 07, 2026 Revance Therapeutics has a market cap of $ 309 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Revance Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 479 M | 2.52 B | 900 M | 1.48 B | 970 M | 638 M | 1.03 B | 540 M | 505 M | 312 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.52 B | 312 M | 936 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.25 | 1.81 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 91.28 | 0.11 % | $ 27.2 B | ||
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
28.2 M | $ 0.44 | -16.64 % | $ 5.04 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
3.04 B | $ 24.98 | 1.17 % | $ 3.05 B | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 10.14 | -0.29 % | $ 135 M | ||
|
Cardiff Oncology
CRDF
|
116 M | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
9.48 M | $ 0.53 | -3.07 % | $ 6.98 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Crinetics Pharmaceuticals
CRNX
|
4.11 B | $ 37.7 | 1.26 % | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 49.15 | -0.73 % | $ 4.42 B | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 2.96 | -1.0 % | $ 252 M | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
CytomX Therapeutics
CTMX
|
931 M | $ 4.4 | -3.51 % | $ 607 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Citius Pharmaceuticals
CTXR
|
24.2 M | $ 0.86 | 0.67 % | $ 5.79 M | ||
|
Cue Biopharma
CUE
|
29.4 M | $ 0.18 | -1.61 % | $ 17.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
Aquestive Therapeutics
AQST
|
467 M | $ 4.09 | -0.97 % | $ 437 M | ||
|
Cyclerion Therapeutics
CYCN
|
6.55 M | $ 4.15 | -32.52 % | $ 10.4 M | ||
|
Daré Bioscience
DARE
|
16.9 M | $ 1.81 | 4.02 % | $ 20.2 M | ||
|
DBV Technologies S.A.
DBVT
|
2.82 B | $ 20.36 | -3.32 % | $ 2.84 B | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Denali Therapeutics
DNLI
|
3.04 B | $ 19.38 | -6.15 % | $ 3.19 B | ||
|
Dyadic International
DYAI
|
31.5 M | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
2.04 B | $ 31.37 | 1.0 % | $ 2.08 B | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M |